| Field | Specification |
|---|---|
| Mfr No | |
| Clonality | |
| Host | |
| Immunogen | E.coli-derived human CIT recombinant protein (Position: Q470-H1505) was used as the immunogen for the CIT antibody. |
| Isotype | |
| Product Type | |
| Purity | |
| Reactivity | |
| Storage | |
| Target | |
| UniProt # |
Overview
CIT Antibody / Citron Rho-interacting kinase is a anti-CIT Rabbit antibody Polyclonal (rabbit origin) supplied in Lyophilized format. Recommended for workflows such as Western blot (WB), Flow cytometry (FACS), ELISA with listed reactivity in Human, Mouse, Rat.
Key elements and design rationale
- Target: CIT
- Antibody details: Rabbit, Polyclonal (rabbit origin), isotype Rabbit IgG
- Format: Lyophilized
- Applications (as listed): WB, FACS, ELISA
Biological background
CIT is encoded by the CIT gene located on human chromosome 12q23.1. The protein is approximately 230 kilodaltons and contains an N-terminal kinase domain, a coiled-coil region, a Rho-binding domain, and a C-terminal citron homology region with multiple protein-protein interaction motifs. CIT localizes to the midbody during cytokinesis and to dendritic spines in postmitotic neurons.
The CIT antibody detects the 230 kilodalton protein in western blot analysis and reveals distinct midbody and dendritic staining patterns. CIT acts as a scaffold and kinase that phosphorylates substrates including myosin light chain and actin-regulatory proteins, coordinating contraction during cell division. Depletion of CIT disrupts cleavage furrow ingression and leads to multinucleation due to failed cytokinesis.
In the nervous system, Citron kinase contributes to dendrite formation, axon stability, and synaptic maturation. Mutations in CIT cause microcephaly and neuronal migration disorders due to abnormal mitotic spindle dynamics and impaired cell cycle progression in neural progenitors. CIT also interacts with RhoA and other GTPases, integrating cytoskeletal signaling with cortical actin organization.
CIT is a critical effector of Rho-mediated contractility and has been implicated in cancer cell proliferation and migration.
Research relevance and current trends
- Connecting protein-level changes to phenotype using orthogonal readouts (genetic perturbation, transcriptomics, imaging).
- Considering isoforms and post-translational regulation when interpreting protein-level changes.
- Comparing results across species and model systems with matched controls.
Common research applications
- Western blotting: compare relative abundance and activation-state changes across conditions.
- Flow cytometry: quantify target-positive populations and signal shifts at single-cell resolution.
- ELISA: support antibody-based quantification in assay formats where applicable.
Interpret changes in signal alongside appropriate controls and, when relevant, in parallel with total-protein or pathway readouts.
Notes for experimental interpretation
- Signal can reflect expression level, isoform composition, and post-translational state; interpret results in the context of your model system and stimuli.
- Species differences and sample matrices can influence epitope recognition; prioritize matched controls and orthogonal confirmation when feasible.
Antibody notes: Polyclonal antibodies recognize multiple epitopes, which can broaden the epitope footprint and may increase sensitivity in some contexts.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
